Resveratrol Trial Halted for Kidney Toxicity
D
Dr Brad Stanfield reports on the adverse effects of Resveratrol trials in cancer patients.
General HealthMedical
Story of claim
Clinical trials of micronized Resveratrol in multiple myeloma patients were terminated due to severe kidney toxicity, highlighting safety concerns.
- Goal: Assess Resveratrol's safety and efficacy in cancer treatment.
- Proof: Severe side effects led to trial termination, indicating significant safety risks.
- Nuances:
- Focus was on micronized Resveratrol for better absorption.
- Conducted by GSK with a focus on cancer patients.
- Severe side effects observed, leading to early termination.
- Impact on Life: The findings raise significant safety concerns and halted further research.
Investments
- Price:
- Time:
- Effort: Clinical trial efforts were extensive, but outcomes were negative.
Risks
Severe kidney toxicity observed, leading to trial termination.
Get Started 🚀
- Understand the clinical trial protocols and outcomes.
- Review safety profiles of similar compounds.
- Consult with healthcare providers before considering Resveratrol.
Brogevity AI can make mistakes. Check important info.